Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Psoriatic Arthritis

NCT05640245 is registered in ClinicalTrials.gov with MoonLake Immunotherapeutics AG as lead sponsor.

NCT NCT05640245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05640245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Psoriatic Arthritis
Lead sponsor
MoonLake Immunotherapeutics AG
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2022
Completion date
January 15, 2024
Enrollment
207 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic